Despite the aforementioned potentially toxic profile and limitations of TDM, Tac remains the most relevant immunosuppressant in therapy of patients after solid organ transplantation, which has led to a broad variety of studies addressing Tac metabolism and optimization of dosing
Subcutaneous fat (the pinchable layer under skin) reduces more gradually
The Drugs@FDA database contains no entry for BPC-157 in any indication, and ClinicalTrials.gov shows no ongoing human studies registered in the United States
It can promote fatty acid oxidation and reduce hepatic lipogenesis, which may be particularly relevant for patients with obesity, insulin resistance, metabolic dysfunction-associated steatotic liver disease, or type 2 diabetes
Glutathione has a well-documented absorption problem: taken orally, much of it breaks down during digestion before the body can use it
3.4 Changing clinical and regulatory expectations Finally, shifts in clinical and regulatory expectations have altered the landscape in which peptide therapeutics are evaluated